Trial
NCT05825365
Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
AstraZeneca
Collaborators
—
Condition
Neurofibromatosis Type 1
Intervention
Selumetinib
Why stopped
Selumetinib launch approval achieved in advance,strategy changesa new study will be generated in place of this study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-14